Foxo1 mediates insulin action on apoC-III and triglyceride metabolism.
The apolipoprotein apoC-III plays an important role in plasma triglyceride metabolism. It is predominantly produced in liver, and its hepatic expression is inhibited by insulin. To elucidate the inhibitory mechanism of insulin in apoC-III expression, we delivered forkhead box O1 (Foxo1) cDNA to hepatocytes by adenovirus-mediated gene transfer. Foxo1 stimulated hepatic apoC-III expression and correlated with the ability of Foxo1 to bind to its consensus site in the apoC-III promoter. Deletion or mutation of the Foxo1 binding site abolished insulin response and Foxo1-mediated stimulation. Likewise, Foxo1 also mediated insulin action on intestinal apoC-III expression in enterocytes. Furthermore, elevated Foxo1 production in liver augmented hepatic apoC-III expression, resulting in increased plasma triglyceride levels and impaired fat tolerance in mice. Transgenic mice expressing a constitutively active Foxo1 allele exhibited hypertriglyceridemia. Moreover, we show that hepatic Foxo1 expression becomes deregulated as a result of insulin deficiency or insulin resistance, culminating in significantly elevated Foxo1 production, along with its skewed nuclear distribution, in livers of diabetic NOD or db/db mice. While loss of insulin response is associated with unrestrained apoC-III production and impaired triglyceride metabolism, these data suggest that Foxo1 provides a molecular link between insulin deficiency or resistance and aberrant apoC-III production in the pathogenesis of diabetic hypertriglyceridemia.
Altomonte
Jennifer
J
Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Cong
Lin
L
Harbaran
Sonal
S
Richter
Anja
A
Xu
Jing
J
Meseck
Marcia
M
Dong
Hengjiang Henry
HH
D000256:Adenoviridae / Q000235:genetics; D000483:Alleles; D000818:Animals; D001056:Apolipoproteins C / Q000097:blood / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D001665:Binding Sites / Q000235:genetics; D018938:Caco-2 Cells; D002460:Cell Line; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D020895:Enterocytes / Q000378:metabolism; D017930:Genes, Reporter; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D015228:Hypertriglyceridemia / Q000235:genetics; D007328:Insulin / Q000378:metabolism* / Q000494:pharmacology; D008156:Luciferases / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D011401:Promoter Regions, Genetic; D051381:Rats; D014157:Transcription Factors / Q000235:genetics* / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism*
D001056:Apolipoproteins C; D007328:Insulin; D014157:Transcription Factors; D014280:Triglycerides; D008156:Luciferases